Amgen To Issue Biotech Cost-Effectiveness Study For Key Therapeutic Areas
This article was originally published in The Pink Sheet Daily
Executive Summary
The “Value of Biotechnology” study will examine the impact of biotech products on the social and economic burden of diseases such as asthma, stroke and diabetes.
You may also be interested in...
BIO Priorities Include Appropriate Pricing, Chair Mullen Says
Biotechnology Industry Organization will also work to strengthen the intellectual property system, the exec tells BIO’s annual meeting.
Genentech Pricing Strategy Is “Good For Society,” CEO Says
Levinson defends the high cost of targeted cancer treatments while suggesting the price of Avastin will increase.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter